Holen Sie sich die Stockscreener-App
151.18
2.32%
-3.62
Schlusskurs vom Vortag:
$154.80
Offen:
$154.25
24-Stunden-Volumen:
390.60K
Relative Volume:
0.44
Marktkapitalisierung:
$15.00B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
51.25
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+5.59%
1M Leistung:
+10.38%
6M Leistung:
+24.34%
1J Leistung:
+21.97%
1-Tages-Spanne:
$150.89
$154.50
1-Wochen-Bereich:
$139.46
$157.67
52-Wochen-Spanne:
$84.23
$157.67
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
151.20 | 15.43B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
119.67 | 52.69B | 9.40B | 2.65B | 2.22B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.66 | 43.09B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.499 | 41.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
23.95 | 28.06B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.53 | 19.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Applying sector rotation models to Neurocrine Biosciences Inc.Market Sentiment Review & Safe Capital Preservation Plans - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changesJuly 2025 Retail & Growth Focused Stock Reports - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherChart Signals & Daily Momentum Trading Reports - newser.com
Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? - sharewise.com
Why Neurocrine Biosciences Inc. stock remains resilient2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Neurocrine Biosciences stock reaches 52-week high at 154.83 USD By Investing.com - Investing.com Australia
Measuring Neurocrine Biosciences Inc.’s beta against major indicesJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikes2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityMarket Risk Summary & Safe Capital Growth Trade Ideas - newser.com
What valuation multiples suggest for Neurocrine Biosciences Inc. stock2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyMarket Rally & Daily Profit Maximizing Trade Tips - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levelsOil Prices & Short-Term High Return Ideas - newser.com
How risky is Neurocrine Biosciences Inc. stock nowWeekly Market Summary & Advanced Technical Analysis Signals - newser.com
Is Neurocrine Biosciences Inc. stock trading near support levelsMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s future2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Neurocrine Biosciences stock reaches 52-week high at 154.83 USD - Investing.com India
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsDividend Hike & Precise Entry and Exit Recommendations - newser.com
How the Narrative Around Neurocrine Biosciences Is Evolving After Recent Results and Analyst Reactions - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Burney Co. - MarketBeat
Can Neurocrine Biosciences Inc. stock weather global recessionJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Assetmark Inc. Boosts Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Earnings Recap & Verified Short-Term Plans - newser.com
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stockSwing Trade & Safe Entry Point Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Neurocrine Biosciences CEO Gano Kyle sells $42591 in stock By Investing.com - Investing.com Nigeria
Can Neurocrine Biosciences Inc. stock sustain revenue growthMarket Volume Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Neurocrine Biosciences CEO Gano Kyle sells $42591 in stock - Investing.com
What Makes Neurocrine (NBIX) a New Strong Buy Stock - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $179.00 - MarketBeat
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurocrine Biosciences Inc-Aktie (NBIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RASTETTER WILLIAM H | Director |
Nov 05 '25 |
Sale |
151.82 |
18,000 |
2,732,690 |
40,360 |
0.57%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):